Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Non-Current Assets: 2020-2025

Historic Non-Current Assets for Biofrontera (BFRI) over the last 4 years, with Sep 2025 value amounting to $1.0 million.

  • Biofrontera's Non-Current Assets fell 36.78% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 36.78%. This contributed to the annual value of $1.4 million for FY2024, which is 71.16% down from last year.
  • According to the latest figures from Q3 2025, Biofrontera's Non-Current Assets is $1.0 million, which was down 24.49% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Biofrontera's Non-Current Assets peaked at $7.7 million during Q4 2022, and registered a low of $1.0 million during Q3 2025.
  • In the last 3 years, Biofrontera's Non-Current Assets had a median value of $2.8 million in 2024 and averaged $2.9 million.
  • As far as peak fluctuations go, Biofrontera's Non-Current Assets skyrocketed by 49.01% in 2021, and later plummeted by 71.58% in 2025.
  • Over the past 5 years, Biofrontera's Non-Current Assets (Quarterly) stood at $6.8 million in 2021, then rose by 13.92% to $7.7 million in 2022, then plummeted by 37.28% to $4.9 million in 2023, then crashed by 71.16% to $1.4 million in 2024, then crashed by 36.78% to $1.0 million in 2025.
  • Its Non-Current Assets stands at $1.0 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.3 million for Q1 2025.